Download PDF

Introduction

The antithrombotic market is expected to grow to $22 billion by 2017. The growth will mainly be due to the introduction of new agents onto the market, such as prasugrel and rivaroxaban, which will offer significant improvements over the current standards of care (Plavix (clopidogrel) and warfarin, respectively).

Scope

• Description of the competitive landscape in antithrombotics across seven major markets with market definition and overview.
• Event-driven updated sales forecasts for 2008-17 across the seven major markets: US, France, Germany, Italy, Spain, UK and Japan.
• Analysis of major events and brand dynamics affecting the antithrombotics market.

Highlights

The antithrombotic market is demonstrating steady growth with CAGR of 8% over the 2004-07 period. The growth can be mainly attributed to the increased uptake of Plavix (clopidogrel) and Lovenox (enoxaparin) in all of the seven major markets.

The US antithrombotic market's share among the seven major markets is forecast to decrease, from 55% in 2007 to 49% in 2017, due to the 5EU volume sales being largest and the patent expiries in the EU not affecting the brand sales to the same extent as in the US.

New agents (especially rivaroxaban and prasugrel) will be successful at gaining a large share of the antithrombotic market, as they offer significant improvements over the current standards of care. In fact, two of the top three revenue-generating antithrombotics are forecast to be agents currently in development.

Reasons to Purchase

• Quantify the future size and understand the background of the antithrombotics market
• Understand the commercial landscape in terms of new product potential
• Understand the barriers to uptake for novel antidyslipidemics.

View Table Of Contents >